Advertisement
GILD vs JNJ
Which Stock Would AI Choose? Gilead Sciences (GILD) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- Gilead Sciences (GILD) is riding strong momentum in its HIV franchise, with the stock trading near record highs and up roughly 28% year to date.
- Johnson & Johnson (JNJ) delivered a solid quarter but saw its shares slide after softer medical-device (MedTech) results and guidance that came in slightly below Street expectations.
- GILD's growth is concentrated in HIV treatment and prevention, while JNJ offers broader diversification across pharmaceuticals and MedTech.
- Both stocks carry "Buy" consensus ratings, but their recent relative performance and catalysts have diverged meaningfully.
Introduction
Gilead Sciences and Johnson & Johnson are two of the most widely followed names in U.S. healthcare, yet they occupy different corners of the sector. This stock comparison is relevant for investors weighing a high-momentum biopharmaceutical specialist against a diversified healthcare conglomerate. Gilead is a pure-play drugmaker focused heavily on HIV, oncology, and liver disease, while Johnson & Johnson spans innovative medicines and medical devices. Their contrasting business models, growth drivers, and recent price behavior offer a useful lens on market positioning, making the pair a practical case study for both long-term investors and traders tracking relative performance in the healthcare space.
GILD Overview and Recent Performance
Gilead Sciences is a biopharmaceutical company best known for its leadership in HIV treatment and prevention, alongside oncology, hepatitis, and liver-disease portfolios. In recent weeks, GILD has been among the standout performers in large-cap biotech, with shares advancing toward all-time highs and posting a roughly 28% year-to-date gain.
The catalyst behind this move has been sustained strength in the HIV business. Recent quarterly results showed double-digit growth in HIV product sales, led by the flagship treatment Biktarvy and surging demand for prevention therapies, including Descovy and the newer twice-yearly injection Yeztugo. Management has also raised its full-year product sales guidance. A reported net loss in one recent quarter stemmed primarily from non-cash, acquisition-related research and development charges tied to an oncology push, rather than operational weakness. Analysts have largely responded favorably, with several firms maintaining or raising price targets and one upgrading the stock.
JNJ Overview and Recent Performance
Johnson & Johnson is a diversified healthcare company operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). In recent market activity, JNJ reported quarterly sales of roughly $25.4 billion, up about 6% year over year, and raised its full-year adjusted earnings and revenue guidance — a milestone that would take annual sales above $100 billion for the first time.
Despite the headline beat, shares fell sharply around the earnings release, marking one of the stock's larger single-session declines in over a year. The pressure came mainly from the MedTech segment, where cardiovascular and surgery businesses underperformed amid Middle East conflict, pricing pressure in China, and softness at its Abiomed heart-pump unit. The Innovative Medicine division remained the bright spot, with strong contributions from Tremfya, Caplyta, and the newly launched psoriasis drug Icotyde. JNJ also announced plans to spin off its orthopedics business, DePuy Synthes, in a move aimed at sharpening strategic focus.
Trending AI Robots
For traders who prefer a data-driven approach, Tickeron's Trending AI Robots page offers a curated view of the platform's most relevant AI trading bots. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance metrics, and target universe. Because only a subset of these bots fits the current market environment at any given time, the Trending AI Robots section highlights those best suited to prevailing conditions. Whether you are evaluating GILD, JNJ, or other names, reviewing this section can help you identify automated strategies aligned with today's market dynamics.
Head-to-Head Comparison
The clearest contrast between the two names is breadth versus focus. JNJ offers diversification across drugs and devices, which can cushion individual product setbacks but also dilutes the impact of any single catalyst. GILD is more concentrated, meaning its HIV franchise — now accounting for the large majority of product sales — drives the bulk of both upside and risk.
Growth drivers also differ. Gilead's story centers on HIV prevention uptake and an emerging oncology pivot funded by recent acquisitions. Johnson & Johnson's narrative leans on new drug launches such as Icotyde and an evolving device portfolio, offset by litigation charges and softer MedTech demand. On recent momentum, GILD has clearly outperformed, trading near record highs, while JNJ has lagged following its latest report. Risk factors include concentration risk for Gilead versus execution and device-recovery risk for JNJ. Sector exposure is another trade-off: GILD is a focused biotech proxy, while JNJ behaves more like a diversified healthcare bellwether.
Tickeron AI Verdict
Based on observable trend consistency and relative positioning, Tickeron's AI would currently lean toward GILD. The stock exhibits a firmer and more persistent uptrend, sustained positive catalysts in its core HIV franchise, and analyst support near record levels. JNJ, by contrast, shows greater stability from diversification but weaker recent momentum and a more mixed earnings reaction. In probabilistic terms, GILD's trend profile and near-term catalyst momentum currently present the stronger relative setup, though JNJ's stability and defensive characteristics remain a meaningful counterweight for risk-averse investors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Buy and JNJ is a Hold.
Momentum Indicator for GILD turns positive, indicating new upward trend
GILD saw its Momentum Indicator move above the 0 level on October 14, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In 57 of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GILD just turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 37 of 55 cases over the following month. The odds of a continued upward trend are 67%.
Following a +6.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 216 of 336 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 141 of 272 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 61 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 23 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.407) is normal, around the industry mean (-3.286). GILD's P/E Ratio (-59.966) is considerably lower than the industry average of (20.679). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
JNJ sees its Stochastic Oscillator ascends from oversold territory
On October 09, 2026, the Stochastic Oscillator for JNJ moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 50 instances where the indicator left the oversold zone. In 25 of the 50 cases the stock moved higher in the following days. This puts the odds of a move higher at over 50%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Oscillator exited the oversold zone, 10 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 33%.
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on JNJ as a result. In 39 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 46%.
Following a +2.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
JNJ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
JNJ moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for JNJ crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 65%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
The Aroon Indicator for JNJ entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.356) is normal, around the industry mean (-3.286). P/E Ratio (29.709) is within average values for comparable stocks, (20.679). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.021) settles around the average of (0.041) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
GILD | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 24 Undervalued | 76 Overvalued | |
PROFIT vs RISK RATING 1..100 | 9 | 4 | |
SMR RATING 1..100 | 96 | 37 | |
PRICE GROWTH RATING 1..100 | 23 | 45 | |
P/E GROWTH RATING 1..100 | 100 | 8 | |
SEASONALITY SCORE 1..100 | 35 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (24) in the Biotechnology industry is somewhat better than the same rating for JNJ (76) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (4) in the Pharmaceuticals Major industry is in the same range as GILD (9) in the Biotechnology industry. This means that JNJ’s stock grew similarly to GILD’s over the last 12 months.
JNJ's SMR Rating (37) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (96) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than GILD’s over the last 12 months.
GILD's Price Growth Rating (23) in the Biotechnology industry is in the same range as JNJ (45) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's P/E Growth Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (100) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than GILD’s over the last 12 months.
| GILD | JNJ | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 33% |
| Stochastic ODDS (%) | 2 days ago 54% | 2 days ago 50% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 46% |
| MACD ODDS (%) | 2 days ago 67% | N/A |
| TrendWeek ODDS (%) | 2 days ago 63% | 2 days ago 47% |
| TrendMonth ODDS (%) | 2 days ago 65% | 2 days ago 44% |
| Advances ODDS (%) | 7 days ago 64% | 10 days ago 46% |
| Declines ODDS (%) | 3 days ago 47% | 17 days ago 40% |
| BollingerBands ODDS (%) | 2 days ago 50% | 2 days ago 45% |
| Aroon ODDS (%) | 2 days ago 52% | 2 days ago 42% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green while JNJ’s FA Score has 2 green FA rating(s).
- GILD’s FA Score: 3 green, 2 red.
- JNJ’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 4 TA indicator(s) are bullish while JNJ’s TA Score has 5 bullish TA indicator(s).
- GILD’s TA Score: 4 bullish, 3 bearish.
- JNJ’s TA Score: 5 bullish, 4 bearish.
Price Growth
GILD (@Pharmaceuticals: Major) experienced а +5.81% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +4.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.72%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +3.76%.
Reported Earning Dates
GILD is expected to report earnings on Oct 29, 2026.
JNJ is expected to report earnings on Jan 26, 2027.
Industries' Descriptions
@Pharmaceuticals: Major (+0.72% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with ABBV. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then ABBV could also see price increases.